MetaVia Inc. announced positive results from a Phase 2a clinical trial for a treatment related to metabolic dysfunction-associated steatohepatitis (MASH). The press release includes forward-looking statements and is not considered a formal filing under securities laws.
AI Assistant
METAVIA INC
2024
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.